Rating
Buy
Price target
$880
Previous
$840
Implied upside
+32%

Piper Sandler analyst Thomas Champion raised the price target on Meta (NASDAQ: META) to $880.00 (from $840.00) while maintaining an Overweight rating.

“META reported a very strong 4Q topline and 1Q guide although FY26 opex / capex were both well above bogeys. 4Q revenue and EBITDA were 2% and 4% above expects (vs 4% and 8% in 3Q25).

The 1Q revenue guide was particularly strong +30% y/y cc at the highend. Full-year CAPEX & OPEX also move substantially higher.

Despite the magnitude of investment, we’re raising ’26 EBIT and the impact on revenue is tangible.

META remains our top large cap pick. PT moves to $880 from $840. Reiterate OW. 4Q revenue results were impressive and guidance was higher across all metrics. There’s palpable confidence.

Mgmt is investing massively into AI, but showing tangible ROI with 1Q rev guide +30% y/y cc at the highend. We remain bullish on ad model investments like GEM and Andromeda.

The tools are working, and we expect further improvements, plus potential for new AI tools. Our ’27 revenues / EBITDA estimates move 6% / 7% while PT moves to $880 from $840. Reiterate OW.”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.